Is the choice of vaccine adjuvant critical for long-term memory development?

References

• Ahmed R, Gray D. Immunological memory and protective immunity: understanding their relation. Science272(5258),54–60 (1996).
   PubMed Web of Science ®Google Scholar
• Castellino F, Galli G, Del Giudice G, Rappuoli R. Generating memory with vaccination. Eur. J. Immunol.39(8),2100–2105 (2009).
   PubMed Web of Science ®Google Scholar
• Amanna IJ, Carlson NE, Slifka MK. Duration of humoral immunity to common viral and vaccine antigens. N. Engl. J. Med.357(19),1903–1915 (2007).
   PubMed Web of Science ®Google Scholar
• Querec TD, Akondy RS, Lee EK et al. Systems biology approach predicts immunogenicity of the yellow fever vaccine in humans. Nat. Immunol.10(1),116–125 (2009).
   PubMed Web of Science ®Google Scholar
• Lycke N. Mechanisms of adjuvant action. In: Vaccine Adjuvants and Delivery Systems. Singh M (Ed.). John Wiley & Sons, NJ, USA, 53–79 (2007).
   Google Scholar
• Ott G, van Nest G. Development of vaccine adjuvants: a historical perspective. In: Vaccine Adjuvants and Delivery Systems. Singh M (Ed.). John Wiley & Sons, NJ, USA, 1–32 (2007).
   Google Scholar
• Lambrecht BN, Kool M, Willart MA, Hammad H. Mechanism of action of clinically approved adjuvants. Curr. Opin. Immunol.21(1),23–29 (2009).
   PubMed Web of Science ®Google Scholar
• Reed SG, Bertholet S, Coler RN, Friede M. New horizons in adjuvants for vaccine development. Trends Immunol.30(1),23–32 (2009).
   PubMed Web of Science ®Google Scholar
• Crotty S, Felgner P, Davies H et al. Cutting edge: long-term B cell memory in humans after smallpox vaccination. J. Immunol.171(10),4969–4973 (2003).
   PubMed Web of Science ®Google Scholar
• Hammarlund E, Lewis MW, Hansen SG et al. Duration of antiviral immunity after smallpox vaccination. Nat. Med.9(9),1131–1137 (2003).
   PubMed Web of Science ®Google Scholar
• Tarlinton D, Radbruch A, Hiepe F, Dorner T. Plasma cell differentiation and survival. Curr. Opin. Immunol.20(2),162–169 (2008).
   PubMed Web of Science ®Google Scholar
• Galli G, Hancock K, Hoschler K et al. Fast rise of broadly cross-reactive antibodies after boosting long-lived human memory B cells primed by an MF59 adjuvanted prepandemic vaccine. Proc. Natl Acad. Sci. USA106(19),7962–7967 (2009).
   PubMed Web of Science ®Google Scholar
• Good-Jacobson KL, Shlomchik MJ. Plasticity and heterogeneity in the generation of memory B cells and long-lived plasma cells: the influence of germinal center interactions and dynamics. J. Immunol.185(6),3117–3125 (2010).
   PubMed Web of Science ®Google Scholar
• Yoshida T, Mei H, Dorner T et al. Memory B and memory plasma cells. Immunol. Rev.237(1),117–139 (2010).
   PubMed Web of Science ®Google Scholar
• Ahlers JD, Belyakov IM. Memories that last forever: strategies for optimizing vaccine T-cell memory. Blood115(9),1678–1689 (2010).
   PubMed Web of Science ®Google Scholar
• Aiba Y, Kometani K, Hamadate M et al. Preferential localization of IgG memory B cells adjacent to contracted germinal centers. Proc. Natl Acad. Sci. USA107(27),12192–12197 (2010).
   PubMed Web of Science ®Google Scholar
• Ahuja A, Anderson SM, Khalil A, Shlomchik MJ. Maintenance of the plasma cell pool is independent of memory B cells. Proc. Natl Acad. Sci. USA105(12),4802–4807 (2008).
   PubMed Web of Science ®Google Scholar
• Anderson SM, Khalil A, Uduman M et al. Taking advantage: high-affinity B cells in the germinal center have lower death rates, but similar rates of division, compared to low-affinity cells. J. Immunol.183(11),7314–7325 (2009).
   PubMed Web of Science ®Google Scholar
• Mamani-Matsuda M, Cosma A, Weller S et al. The human spleen is a major reservoir for long-lived vaccinia virus-specific memory B cells. Blood111(9),4653–4659 (2008).
   PubMed Web of Science ®Google Scholar
• Tokoyoda K, Hauser AE, Nakayama T, Radbruch A. Organization of immunological memory by bone marrow stroma. Nat. Rev. Immunol.10(3),193–200 (2010).
   PubMed Web of Science ®Google Scholar
• Tokoyoda K, Zehentmeier S, Hegazy AN et al. Professional memory CD4+ T lymphocytes preferentially reside and rest in the bone marrow. Immunity30(5),721–730 (2009).
   PubMed Web of Science ®Google Scholar
• Banchereau J, Steinman RM. Dendritic cells and the control of immunity. Nature392(6673),245–252 (1998).
   PubMed Web of Science ®Google Scholar
• Bendelac A, Medzhitov R. Adjuvants of immunity: harnessing innate immunity to promote adaptive immunity. J. Exp. Med.195(5),F19–F23 (2002).
   PubMed Web of Science ®Google Scholar
• Allen CD, Okada T, Cyster JG. Germinal-center organization and cellular dynamics. Immunity27(2),190–202 (2007).
   PubMed Web of Science ®Google Scholar
• Lindquist RL, Shakhar G, Dudziak D et al. Visualizing dendritic cell networks in vivo.Nat. Immunol.5(12),1243–1250 (2004).
   PubMed Web of Science ®Google Scholar
• Colonna M, Pulendran B, Iwasaki A. Dendritic cells at the host–pathogen interface. Nat. Immunol.7(2),117–120 (2006).
   PubMed Web of Science ®Google Scholar
• Kool M, Petrilli V, De Smedt T et al. Cutting edge: alum adjuvant stimulates inflammatory dendritic cells through activation of the NALP3 inflammasome. J. Immunol.181(6),3755–3759 (2008).
   PubMed Web of Science ®Google Scholar
• Liang S, Wang M, Triantafilou K et al. The A subunit of type IIb enterotoxin (LT-IIb) suppresses the proinflammatory potential of the B subunit and its ability to recruit and interact with TLR2. J. Immunol.178(8),4811–4819 (2007).
   PubMed Web of Science ®Google Scholar
• Holmgren J, Czerkinsky C. Mucosal immunity and vaccines. Nat. Med.11(4 Suppl.),S45–S53 (2005).
   PubMed Web of Science ®Google Scholar
• Agren LC, Ekman L, Lowenadler B, Lycke NY. Genetically engineered nontoxic vaccine adjuvant that combines B cell targeting with immunomodulation by cholera toxin A1 subunit. J. Immunol.158(8),3936–3946 (1997).
   PubMed Web of Science ®Google Scholar
• Agren L, Sverremark E, Ekman L et al. The ADP-ribosylating CTA1-DD adjuvant enhances T cell-dependent and independent responses by direct action on B cells involving anti-apoptotic Bcl-2- and germinal center-promoting effects. J. Immunol.164(12),6276–6286 (2000).
   PubMed Web of Science ®Google Scholar
• Eriksson AM, Schon KM, Lycke NY. The cholera toxin-derived CTA1-DD vaccine adjuvant administered intranasally does not cause inflammation or accumulate in the nervous tissues. J. Immunol.173(5),3310–3319 (2004).
   PubMed Web of Science ®Google Scholar
• Fujihashi K, Koga T, van Ginkel FW, Hagiwara Y, McGhee JR. A dilemma for mucosal vaccination: efficacy versus toxicity using enterotoxin-based adjuvants. Vaccine20(19–20),2431–2438 (2002).
   PubMed Web of Science ®Google Scholar
• Mutsch M, Zhou W, Rhodes P et al. Use of the inactivated intranasal influenza vaccine and the risk of Bell’s palsy in Switzerland. N. Engl. J. Med.350(9),896–903 (2004).
   PubMed Web of Science ®Google Scholar
• Lycke N. Targeted vaccine adjuvants based on modified cholera toxin. Curr. Mol. Med.5(6),591–597 (2005).
   PubMed Web of Science ®Google Scholar
• Sundling C, Schon K, Morner A et al. CTA1-DD adjuvant promotes strong immunity against human immunodeficiency virus type 1 envelope glycoproteins following mucosal immunization. J. Gen. Virol.89(Pt 12),2954–2964 (2008).
   PubMed Web of Science ®Google Scholar
• Plotkin SA. Vaccines: correlates of vaccine-induced immunity. Clin. Infect. Dis.47(3),401–409 (2008).
   PubMed Web of Science ®Google Scholar
• Straight TM, Ottolini MG, Prince GA, Eichelberger MC. Antibody contributes to heterosubtypic protection against influenza A-induced tachypnea in cotton rats. Virol. J.5, 44 (2008).
   PubMed Web of Science ®Google Scholar
• Delgado MF, Coviello S, Monsalvo AC et al. Lack of antibody affinity maturation due to poor Toll-like receptor stimulation leads to enhanced respiratory syncytial virus disease. Nat. Med.15(1),34–41 (2009).
   PubMed Web of Science ®Google Scholar
• Dorner T, Radbruch A. Antibodies and B cell memory in viral immunity. Immunity27(3),384–392 (2007).
   PubMed Web of Science ®Google Scholar
• Vakiani E, Basso K, Klein U et al. Genetic and phenotypic analysis of B-cell post-transplant lymphoproliferative disorders provides insights into disease biology. Hematol. Oncol.26(4),199–211 (2008).
   PubMed Web of Science ®Google Scholar
• McHeyzer-Williams LJ, McHeyzer-Williams MG. Antigen-specific memory B cell development. Annu. Rev. Immunol.23, 487–513 (2005).
   PubMed Web of Science ®Google Scholar
• Takahashi Y, Ohta H, Takemori T. Fas is required for clonal selection in germinal centers and the subsequent establishment of the memory B cell repertoire. Immunity14(2),181–192 (2001).
   PubMed Web of Science ®Google Scholar
• Yu D, Rao S, Tsai LM et al. The transcriptional repressor Bcl-6 directs T follicular helper cell lineage commitment. Immunity31(3),457–468 (2009).
   PubMed Web of Science ®Google Scholar
• Tangye SG, Tarlinton DM. Memory B cells: effectors of long-lived immune responses. Eur. J. Immunol.39(8),2065–2075 (2009).
   PubMed Web of Science ®Google Scholar
• Zotos D, Coquet JM, Zhang Y et al. IL-21 regulates germinal center B cell differentiation and proliferation through a B cell-intrinsic mechanism. J. Exp. Med.207(2),365–378 (2010).
   PubMed Web of Science ®Google Scholar
• Mackay F, Schneider P, Rennert P, Browning J. BAFF and APRIL: a tutorial on B cell survival. Annu. Rev. Immunol.21, 231–264 (2003).
   PubMed Web of Science ®Google Scholar
• Braun MC, He J, Wu CY, Kelsall BL. Cholera toxin suppresses interleukin (IL)-12 production and IL-12 receptor b1 and b2 chain expression. J. Exp. Med.189(3),541–552 (1999).
   PubMed Web of Science ®Google Scholar
• Cong Y, Oliver AO, Elson CO. Effects of cholera toxin on macrophage production of co-stimulatory cytokines. Eur. J. Immunol.31(1),64–71 (2001).
   PubMed Web of Science ®Google Scholar
• Lavelle EC, Jarnicki A, McNeela E et al. Effects of cholera toxin on innate and adaptive immunity and its application as an immunomodulatory agent. J. Leukoc. Biol.75(5),756–763 (2004).
   PubMed Web of Science ®Google Scholar
• Williamson E, Westrich GM, Viney JL. Modulating dendritic cells to optimize mucosal immunization protocols. J. Immunol.163(7),3668–3675 (1999).
   PubMed Web of Science ®Google Scholar
• Sjöblom-Hallén A, Marklund U, Nerstedt A et al. Gene expression profiling identifies STAT3 as a novel pathway for immunomodulation by cholera toxin adjuvant. Muc. Immunol.3(4),374–386 (2010).
   PubMed Web of Science ®Google Scholar
• Lycke N, Holmgren J. Intestinal mucosal memory and presence of memory cells in lamina propria and Peyer’s patches in mice 2 years after oral immunization with cholera toxin. Scand. J. Immunol.23(5),611–616 (1986).
   PubMed Web of Science ®Google Scholar
• Lycke N, Holmgren J. Adoptive transfer of gut mucosal antitoxin memory by isolated B cells 1 year after oral immunization with cholera toxin. Infect. Immun.57(4),1137–1141 (1989).
   PubMed Web of Science ®Google Scholar
• Bemark M, Bergqvist P, Holmberg A, Mattsson J, Stensson A, Lycke NY. A unique role of the CTA1-DD adjuvant for long-term plasma and memory B cell development. J. Immunol. (In press) (2010).
   PubMed Web of Science ®Google Scholar
• Cunningham KA, Carey AJ, Lycke N, Timms P, Beagley KW. CTA1-DD is an effective adjuvant for targeting anti-chlamydial immunity to the murine genital mucosa. J. Reprod. Immunol.81(1),34–38 (2009).
   PubMed Web of Science ®Google Scholar